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Discussion
Dr Frank W. Sellke (Boston, MA). Joe, This is a very nice
extension of what was presented at the American Heart Associa-
tion last year. It suggests that cyclin A2 may increase myocardial
regeneration and may have some therapeutic effect in treatment of
patients with chronic heart failure. I do have a couple of questions.
How did the cyclin A2 affect other cell cycle proteins and factors
regulating myocardial regeneration and function? You may have
looked at this previously, but do you have data?
Dr Y. Joseph Woo (Philadelphia, Pa). There is work done in
the transgenic mouse that constitutively expressed cyclin A2.
There did not appear to be much change in the other cell cycle
regulators. It seems that cyclin A was working independently of
manipulation of the other factors in the cell cycle regulation
pathway.
Dr Sellke. The other question I have is a follow-up to that
question. How does manipulation of cyclin A2 affect long-term
viability? Could it just be a short-term effect with aggression of
these new cells at a later date?
Dr Woo. Yes. Cyclin D has been evaluated in a similar fashion
by others. And although there is some controversy regarding
whether that is actually effective, similar results have been shown.
Cyclin D is notable for its control of the restriction point, that is,
the G1, theoretical G0 point interaction. Cyclin A is particularly
interesting, primarily for the points that I mentioned earlier. It is a
2-point controller. It drives G1 into DNA synthesis. There are
various factors that can drive proliferation but not actually repli-
cation. You need to actually be able to push a cell into mitosis to
make a difference. Cyclin A also regulates this control point.
Furthermore, a cyclin A2 knockout is an embryonic lethal variant
and also, it is totally silenced in the adult, thus making it an
appealing therapeutic target.
Dr Sellke. Have you looked at targeting 2-cell cycle regulator
factors simultaneously?
Dr Woo. That is a good idea. I think the thing to do here would
be to use cyclins D and A. Cyclin D would allow the cells to come
out of the theoretical G0 state, and then cyclin A would push the
cells into S and then over into M state.
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